Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

With early efficacy signals emerging from a dose-finding study, Cyteir will use its new $80 million series C crossover round to gain Phase II data in multiple cancers for its DNA damage repair (DDR) molecule targeting RAD51, the only one in its class to reach the clinic.

RA Capital led the round for Cyteir Therapeutics Inc., bringing the biotech’s total amount raised to more than $140 million since its 2016 series A. President and CEO Markus Renschler told BioCentury the company hopes to move forward with a public offering as soon as this year...